Drug Use Investigation for XYZAL®

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Rhinitis, Allergic, Perennial and Seasonal

Treatments: Drug: Levocetirizine

Study type: Observational

Funder types: Industry

Identifiers

NCT01445262

115066

Details and patient eligibility

About

This post-marketing surveillance study (PMS) is conducted to collect safety and efficacy data among subjects with allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous who have never been treated with levocetirizine tablets before.

Enrollment: 10,728 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must be the first time for taking levocetirizine tablet

Exclusion criteria

• As this is PMS study, there are no exclusion criteria.

Trial design

10,728 participants in 1 patient group

Subjects prescribed levocetirizine tablets

Description:

Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous

Treatment:

Drug: Levocetirizine